Show simple item record

dc.contributor.authorTripathi, R.
dc.contributor.authorArchibald, L.K.
dc.contributor.authorMazmudar, R.S.
dc.contributor.authorConic, R.R.Z.
dc.contributor.authorRothermel, L.D.
dc.contributor.authorScott, J.F.
dc.contributor.authorBordeaux, J.S.
dc.date.accessioned2020-07-22T20:17:10Z
dc.date.available2020-07-22T20:17:10Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85087781736&doi=10.1016%2fj.jaad.2020.03.094&partnerID=40&md5=1f4f33fad59f3cea3a673c86f56dc542
dc.identifier.urihttp://hdl.handle.net/10713/13388
dc.description.abstractBackground: Longer time from diagnosis to definitive surgery (TTDS) is associated with increased melanoma-specific mortality. Although black patients present with later-stage melanoma and have worse survival than non-Hispanic white patients, the association between race and TTDS is unknown. Objective: To investigate racial differences in time to melanoma treatment. Methods: Retrospective review of the National Cancer Database (2004-2015). Multivariable logistic regression was used to evaluate the association of race with TTDS, controlling for sociodemographic/disease characteristics. Results: Of the 233,982 patients with melanoma identified, 1221 (0.52%) were black. Black patients had longer TTDS for stage I to III melanoma (P < .001) and time to immunotherapy (P = .01), but not for TTDS for stage IV melanoma or time to chemotherapy (P >. 05 for both). When sociodemographic characteristics were controlled for, black patients had over twice the odds of having a TTDS between 41 and 60 days, over 3 times the odds of having a TTDS between 61 and 90 days, and over 5 times the odds of having a TTDS over 90 days. Racial differences in TTDS persisted within each insurance type. Patients with Medicaid had the longest TTDS (mean, 60.4 days), and those with private insurance had the shortest TTDS (mean, 44.6 days; P < .001 for both). Conclusions: Targeted approaches to improve TTDS for black patients are integral in reducing racial disparities in melanoma outcomes.en_US
dc.description.urihttps://doi.org/10.1016/j.jaad.2020.03.094en_US
dc.language.isoen_USen_US
dc.publisherMosby Inc.en_US
dc.relation.ispartofJournal of the American Academy of Dermatology
dc.subjectblacken_US
dc.subjectchemotherapyen_US
dc.subjectdisparitiesen_US
dc.subjectimmunotherapyen_US
dc.subjectinsuranceen_US
dc.subjectmelanomaen_US
dc.subjectmortalityen_US
dc.subjectNational Cancer Databaseen_US
dc.subjectnon-Hispanic whiteen_US
dc.subjectracialen_US
dc.subjectstageen_US
dc.subjectsurvivalen_US
dc.subjecttime to definitive surgeryen_US
dc.subjecttime to treatmenten_US
dc.titleRacial differences in time to treatment for melanomaen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jaad.2020.03.094
dc.identifier.pmid32277971


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record